ES2641246T3 - Tratamiento de alergia con enterotoxina termolábil de E. coli destoxificada - Google Patents

Tratamiento de alergia con enterotoxina termolábil de E. coli destoxificada Download PDF

Info

Publication number
ES2641246T3
ES2641246T3 ES10848606.9T ES10848606T ES2641246T3 ES 2641246 T3 ES2641246 T3 ES 2641246T3 ES 10848606 T ES10848606 T ES 10848606T ES 2641246 T3 ES2641246 T3 ES 2641246T3
Authority
ES
Spain
Prior art keywords
detoxified
thermolabile enterotoxin
allergy treatment
coli
coli thermolabile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10848606.9T
Other languages
English (en)
Inventor
Yu-Shen Hsu
Jiu-yao WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Development Center for Biotechnology
Original Assignee
Development Center for Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Development Center for Biotechnology filed Critical Development Center for Biotechnology
Application granted granted Critical
Publication of ES2641246T3 publication Critical patent/ES2641246T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una enterotoxina termolábil de E. coli destoxificada (LT) para su uso en el tratamiento de la alergia en las vías respiratorias en un sujeto mediante administración intranasal de una cantidad eficaz para inducir una respuesta antialérgica en el sujeto, en donde la LT destoxificada es LTS61K, que contiene una subunidad A mutada que contiene una mutación de serina a lisina en la posición correspondiente a la posición 61 en la SEQ ID NO:1 y en donde LTS61K induce la respuesta antialérgica.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES10848606.9T 2010-03-23 2010-05-03 Tratamiento de alergia con enterotoxina termolábil de E. coli destoxificada Active ES2641246T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/729,649 US8241608B2 (en) 2010-03-23 2010-03-23 Treating allergy with detoxified E. coli heat-labile enterotoxin
US729649 2010-03-23
PCT/US2010/033336 WO2011119174A1 (en) 2010-03-23 2010-05-03 Treating allergy with detoxified e. coli heat-labile enterotoxin

Publications (1)

Publication Number Publication Date
ES2641246T3 true ES2641246T3 (es) 2017-11-08

Family

ID=44656764

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10848606.9T Active ES2641246T3 (es) 2010-03-23 2010-05-03 Tratamiento de alergia con enterotoxina termolábil de E. coli destoxificada

Country Status (8)

Country Link
US (1) US8241608B2 (es)
EP (1) EP2550013B1 (es)
JP (1) JP5801868B2 (es)
CN (2) CN107375916A (es)
DK (1) DK2550013T3 (es)
ES (1) ES2641246T3 (es)
TW (1) TWI382088B (es)
WO (1) WO2011119174A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI506135B (zh) * 2012-10-24 2015-11-01 突變型大腸桿菌忌熱毒素、其製備方法、增加免疫反應之佐劑及疫苗
WO2016058939A1 (en) * 2014-10-14 2016-04-21 Premune Ab Use of superantigens for improving mucosal allergen specific immunotherapy in non-human mammals
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法
CN113151334A (zh) * 2021-04-22 2021-07-23 成都亿妙生物科技有限公司 一种幽门螺杆菌LuxS六聚体重组蛋白的发酵和纯化工艺
WO2023250522A2 (en) * 2022-06-25 2023-12-28 Administrators Of The Tulane Educational Fund Vaccine adjuvants and methods

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008101A (en) 1934-02-08 1935-07-16 George W Haury Valve washer
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9800487D0 (en) 1998-01-09 1998-03-04 Oratol Limited Therapies
US6033673A (en) 1998-03-18 2000-03-07 The Administrators Of Tulane Educational Fund Double mutant enterotoxin for use as an adjuvant
WO1999047164A1 (en) 1998-03-18 1999-09-23 The Administrators Of The Tulane Educational Fund Use of mutant enterotoxin with excess b-subunit as an adjuvant
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
JP2003012556A (ja) * 2001-06-29 2003-01-15 Pola Chem Ind Inc アレルギー用の医薬組成物
SE0201701D0 (sv) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
CN1696291A (zh) * 2004-07-15 2005-11-16 中国人民解放军第三军医大学 一种大肠杆菌不耐热肠毒素新型突变体及其制备方法
US8110197B2 (en) * 2006-10-27 2012-02-07 Development Center For Biotechnology Mutated E. coli heat-labile enterotoxin
TWI304838B (en) * 2006-10-27 2009-01-01 Dev Center Biotechnology Nucleotide acid sequence and amino acid sequence of e. coli heat-labile enterotoxin, and recombinant protein
JP5576792B2 (ja) * 2007-07-18 2014-08-20 ディベロップメント センター フォー バイオテクノロジー 変異型大腸菌易熱性エンテロトキシン
EP2219669A4 (en) * 2007-12-19 2011-03-09 Mivac Dev Aktiebolag COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND ALLERGIC DISEASES

Also Published As

Publication number Publication date
EP2550013A4 (en) 2014-03-19
US20110236424A1 (en) 2011-09-29
EP2550013A1 (en) 2013-01-30
JP5801868B2 (ja) 2015-10-28
JP2013522360A (ja) 2013-06-13
WO2011119174A1 (en) 2011-09-29
TWI382088B (zh) 2013-01-11
CN107375916A (zh) 2017-11-24
US8241608B2 (en) 2012-08-14
DK2550013T3 (en) 2017-09-18
TW201132760A (en) 2011-10-01
CN102939099A (zh) 2013-02-20
EP2550013B1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2641246T3 (es) Tratamiento de alergia con enterotoxina termolábil de E. coli destoxificada
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
EA201170381A1 (ru) Получение сквалена из гиперпродуцирующих дрожжей
CU23932B1 (es) Sales farmacéuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo y sus usos en terapia
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
CL2012002954A1 (es) Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros.
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
UY30788A1 (es) Compuestos quimicos
CL2013000991A1 (es) Composicion que comprende polipeptido microbiano blad o variante activo del mismo; uso de dicha composicion para matar o inhibir el crecimiento de un microorganismo que es patogeno humano o animal.